public offering

MAIA Biotechnology prices $30M public offering at $1.50/share to fund clinical trials. Offering closes March 4, 2026.

General Atlantic affiliate sells 13.2M Alignment Healthcare shares at $19.46 in secondary offering, raising ~$257M with expected close March 4, 2026.

MAIA Biotechnology launches underwritten public offering of common stock and pre-funded warrants to fund clinical trials for its lead cancer therapy ateganosine.

Palvella Therapeutics closed $230M public offering at $125/share on February 27, 2026, fully exercising underwriter options to fund rare skin disease programs.

Kratos Defense raises $1.17B through equity offering to fund growth initiatives, capital expenditures, and strategic acquisitions of Nomad and Orbit.

Duos Technologies raises $65M through stock offering to expand its Edge Data Center business segment amid strong 288% revenue growth.

Bicara Therapeutics raises $172.5M in oversubscribed offering, with proceeds funding development of lead immunotherapy candidate ficerafusp alfa for solid tumors.

Larimar Therapeutics raises $100M through expanded share offering at $5 per share, funding development of lead drug candidate nomlabofusp and operations.

Larimar Therapeutics raises $100M through expanded public offering at $5 per share, funding clinical development of rare disease therapeutic candidate nomlabofusp.

Palvella Therapeutics raised $200M through upsized share offering to fund clinical development of rare disease therapies including skin disease and vascular malformation treatments.

Ideal Power raised $14M to commercialize its B-TRAN semiconductor technology, funding customer design-ins, partnerships, and production infrastructure.

Bicara Therapeutics raises $150M through stock and warrant offering to fund lead drug candidate development, expand manufacturing, and build commercial infrastructure.

General Fusion merges with SPAC to go public via Nasdaq under ticker GFUZ, valuing the fusion energy company at $1 billion with closing expected mid-2026.

Bicara Therapeutics plans $150M stock offering to advance its lead drug candidate ficerafusp alfa through clinical development and build commercial infrastructure for potential market launch.

Three major tech companies—AI leader Anthropic, communication platform Discord, and fintech infrastructure firm Plaid—expected to debut on public markets in 2026.

Ideal Power raises $14M through mixed equity financing to accelerate commercialization of its B-TRAN semiconductor technology and expand customer design-ins.

Bimergen Energy raises $13.6M through equity offering to fund battery storage expansion and strengthen operations amid growing grid-scale energy demand.

Eupraxia Pharmaceuticals raises $63.2M to advance its GI disease pipeline, including EP-104GI trials for eosinophilic esophagitis and other gastrointestinal indications.

Candel Therapeutics raises $100M via public share offering to fund commercialization of its prostate cancer gene therapy and ongoing lung cancer clinical trials.

Blue Hat Interactive prices $6.4M unit offering at $0.20 per share. Each unit includes one ordinary share and one warrant, with proceeds for working capital.